Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2020-12-04 4:01 pm Purchase | 13G | 10X CAP VENTURE ACQUISIT CORP VCVCU | CITADEL ADVISORS LLC | 1,350,000 7.7% | 1,350,000 (New Position) | View |
2020-11-30 4:01 pm Purchase | 13G | JIYA ACQUISITION CORP JYAC | CITADEL ADVISORS LLC | 771,996 7.4% | 771,996 (New Position) | View |
2020-11-27 4:03 pm Purchase | 13G | PINE IS ACQUISITION CORP UNIT PIPPU | CITADEL ADVISORS LLC | 1,500,000 6.9% | 1,500,000 (New Position) | View |
2020-11-16 4:02 pm Purchase | 13G | Teligent Inc. TLGT | CITADEL ADVISORS LLC | 203,021 1.4% | 203,021 (New Position) | View |
2020-11-02 4:03 pm Purchase | 13G | HELIX ACQUISITION CORP SH HLXA | CITADEL ADVISORS LLC | 687,919 5.8% | 687,919 (New Position) | View |
2020-10-26 4:01 pm Purchase | 13G | SPRUCE BIOSCIENCES INC SPRB | CITADEL ADVISORS LLC | 1,701,787 7.3% | 1,701,787 (New Position) | View |
2020-10-13 4:08 pm Purchase | 13G | ONCORUS INC ONCR | CITADEL ADVISORS LLC | 1,852,649 8.5% | 1,852,649 (New Position) | View |
2020-10-08 4:02 pm Purchase | 13G | PREVAIL THERAPEUTICS INC PRVL | CITADEL ADVISORS LLC | 2,413,881 7.1% | 2,413,881 (New Position) | View |
2020-09-28 4:03 pm Purchase | 13G | DYNE THERAPEUTICS INC DYN | CITADEL ADVISORS LLC | 2,945,951 6.5% | 2,945,951 (New Position) | View |
2020-08-07 8:09 pm Purchase | 13G | ANNEXON INC ANNX | CITADEL ADVISORS LLC | 2,120,333 5.5% | 2,120,333 (New Position) | View |
2020-07-31 4:31 pm Purchase | 13G | GENOCEA BIOSCIENCES INC NE GNCA | CITADEL ADVISORS LLC | 3,432,386 6.5% | 3,432,386 (New Position) | View |
2020-07-10 4:02 pm Purchase | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | CITADEL ADVISORS LLC | 31,132,991 8.9% | 31,132,991 (New Position) | View |
2020-06-10 5:07 pm Purchase | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | CITADEL ADVISORS LLC | 8,895,435 5% | 8,895,435 (New Position) | View |
2020-04-09 4:01 pm Purchase | 13G | ZENTALIS PHARMACEUTICALS INC C ZNTL | CITADEL ADVISORS LLC | 2,129,964 5.9% | 2,129,964 (New Position) | View |
2020-03-16 4:01 pm Purchase | 13G | LIFESCI ACQUISITION CORP LSACU | CITADEL ADVISORS LLC | 425,449 5.7% | 425,449 (New Position) | View |
2020-02-14 4:07 pm Purchase | 13G | APPLIED OPTOELECTRONICS INC CO AAOI | CITADEL ADVISORS LLC | 2,080,949 9.5% | 423,209 (+25.53%) | View |
2020-02-14 4:07 pm Sale | 13G | SCIPLAY CORP SCPL | CITADEL ADVISORS LLC | 803,264 3.5% | -663,897 (-45.25%) | View |
2020-02-14 4:07 pm Sale | 13G | CYMABAY THERAPEUTICS INC CBAY | CITADEL ADVISORS LLC | 2,934,588 4.3% | -158,341 (-5.12%) | View |
2020-02-14 4:07 pm Purchase | 13G | AVROBIO INC AVRO | CITADEL ADVISORS LLC | 1,689,022 5.3% | 326,367 (+23.95%) | View |
2020-02-14 4:07 pm Sale | 13G | VERASTEM, INC. VSTM | CITADEL ADVISORS LLC | 6,451,987 8% | -933,628 (-12.64%) | View |